Anupam Rasayan reports strong Q2FY26 financials, advances strategic growth

Anupam Rasayan India Ltd. announced unaudited financial results for Q2 and H1 FY26, highlighting a robust performance. Consolidated total revenue for Q2FY26 reached ₹7,392 Mn, a 149% year-over-year (Y-o-Y) increase, with consolidated EBITDA at ₹1,436 Mn (up 74% Y-o-Y) and PAT at ₹572 Mn (up 87% Y-o-Y). For H1FY26, consolidated total revenue was ₹12,299 Mn, growing 121% Y-o-Y.

The company's managing director, Anand Desai, noted that Q2FY26 was "one of the best quarters." Standalone performance also showed strong growth, with Q2FY26 revenue at ₹5,956 Mn (up 206% Y-o-Y) and H1FY26 revenue at ₹9,161 Mn (up 152% Y-o-Y). The company also added 1 new product in Q2FY26, bringing the total to 81 products.

Anupam Rasayan is strategically expanding its polymer and pharma portfolios, with 65+ molecules in R&D and pilot stages and 6 molecules commercialized in FY25. The firm targets a ~$15Bn addressable market in pharmaceuticals with ~5% CAGR (2023-28). The acquisition of a ~26% stake in Tanfac strengthens its fluoro platform with backward integration, securing key raw materials and accessing a $5+Bn addressable market for targeted series.